The p53/p21Cip1/ Waf1 pathway mediates the effects of SPARC on melanoma cell cycle progression
Article first published online: 17 NOV 2010
© 2010 John Wiley & Sons A/S
Pigment Cell & Melanoma Research
Volume 24, Issue 1, pages 219–232, February 2011
How to Cite
Fenouille, N., Robert, G., Tichet, M., Puissant, A., Dufies, M., Rocchi, S., Ortonne, J.-P., Deckert, M., Ballotti, R. and Tartare-Deckert, S. (2011), The p53/p21Cip1/ Waf1 pathway mediates the effects of SPARC on melanoma cell cycle progression. Pigment Cell & Melanoma Research, 24: 219–232. doi: 10.1111/j.1755-148X.2010.00790.x
- Issue published online: 13 JAN 2011
- Article first published online: 17 NOV 2010
- Accepted manuscript online: 18 OCT 2010 08:08AM EST
- PUBLICATION DATA Received 11 August 2010, revised and accepted for publication 13 October 2010, published online 18 October 2010
Figure S1. Validation of shRNA sequences targeting human SPARC.
Figure S2. Depletion of SPARC causes a G2/M cell cycle arrest in melanoma cells.
Figure S3. Effect of conditional RNAi-mediated depletion of SPARC on cell number and cell cycle progression.
Figure S4. Modulation of cell cycle regulators by SPARC siRNA treatment.
Figure S5. p53 is required for the G2/M cell cycle arrest induced by SPARC depletion.
Figure S6. Depletion of SPARC does not modulate MITF levels in melanoma cells.
|PCMR_790_sm_legends.rtf||12K||Supporting info item|
|PCMR_790_sm_FigS1.jpg||3131K||Supporting info item|
|PCMR_790_sm_FigS2.jpg||151K||Supporting info item|
|PCMR_790_sm_FigS3.jpg||173K||Supporting info item|
|PCMR_790_sm_FigS4.jpg||107K||Supporting info item|
|PCMR_790_sm_FigS5.jpg||85K||Supporting info item|
|PCMR_790_sm_FigS6.jpg||182K||Supporting info item|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.